Polymorphic characterization and bioavailability of 20(R)-25-methoxyl-dammarane-3β,12β,20-triol, a novel dammarane triterpenoid saponin, as anticancer agents

    loading  Checking for direct PDF access through Ovid

Abstract

This research, for the first time, obtained and reported three novel Form I, Form II, and Form III of 20(R)-25-methoxyl-dammarane-3β,12β,20-triol polymorphs, which were distinguished by PXRD, IR, DSC, and SEM. This study firstly exploited a rapid and feasible UHPLC-ESI-MS/MS method to determine plasma levels of 20(R)-25-OCH3-PPD within 4.5 min. The composition of mobile phase was acetonitrile and 5 mM ammonium acetate water (85:15, v/v) at a flow rate of 0.2 mL/min on the BEH C18 Column (2.1 mm × 50 mm, 1.7 μm). The approach enhanced the efficiency of analysis compared to reported methods, making a 3-fold reduction in runtimes. The research exhibited that optimal crystal Form I displays higher bioavailability (P < 0.05) compared to the other crystal forms. These findings hold great significance in the early research stages of 20(R)-25-OCH3-PPD polymorphs.

Related Topics

    loading  Loading Related Articles